People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scorpion Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $1.4B | 2024 |
| Halda Therapeutics, LLC | — | Pharma | Series D+ | $197.9M | $1.3B | 2024 |
| Quanta Therapeutics, Inc. | — | Biotechnology | Series C | $120.8M | $699.4M | 2021 |
| Third Arc Bio, Inc. | — | Biotechnology | Series C | $72.5M | $636.7M | 2024 |
| Affini-T Therapeutics, Inc. | — | Biotechnology | Series B | $17.6M | $121.3M | 2024 |
Arjun Goyal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arjun Goyal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Otello Stampacchia | 2 | 4 |
| Jean-Francois Formela | 1 | 17 |
| Shelley Chu | 1 | 10 |
| Tim Shannon | 1 | 9 |
| Gary Glick | 1 | 7 |
| Adam Friedman | 1 | 6 |
| Maha Katabi | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Scott Phillips | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| Nandita Shangari | 1 | 4 |
| Liam Ratcliffe | 1 | 4 |
| Jeffrey Albers | 1 | 3 |
| Oleg Nodelman | 1 | 3 |
| Maria Fardis | 1 | 3 |
| Samuel Saks | 1 | 3 |
| Rebecca Luse | 1 | 3 |
| Joe Cabral | 1 | 2 |
| Brian Piper | 1 | 2 |
| Andrew Fedder | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.